Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial of ifinatamab ...

The progress the UK has made as a global contributor to clinical trials is “remarkable”, says former health minister Lord ...

The shift toward patient-centric trials is real, but challenges in enrolment and retention persist. Patient-centricity has ...

At a recent gathering, experts in the Swiss biotech and pharma sector underscored the power of international collaboration.

Rejuvenate Biomed has dosed the first subject in the randomised Phase II trial to assess its lead compound, RJx-01.

Neurogene said it would conduct daily monitoring for the ‘three Fs’ in the week after dosing with the gene therapy.

IQVIA has partnered with SCRI Development Innovations, the contract research organisation side of the Sarah Cannon Research ...

East Coast conference is set to take place on May 20–21, 2025, at the Valley Forge Casino Resort in King of Prussia, ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...

AviadoBio has opened the multi-centre Phase I/II ASPIRE-FTD trial in the UK, aimed at assessing the gene therapy candidate ...

MSD has reported that the Phase III KEYNOTE-B96 trial of Keytruda plus paclitaxel, with or without bevacizumab, has met its ...

Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...